scholarly journals Second-Line Chemotherapy for Platinum- and Taxane-Resistant Epithelial Ovarian Cancer: Pegylated Liposomal Doxorubicin (PLD), Irinotecan, and Combination Therapies at Lower Doses

10.5772/28554 ◽  
2012 ◽  
Author(s):  
Toru Sugiyama
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Liposomal Doxorubicin ◽  
Pegylated Liposomal Doxorubicin ◽  
Second Line ◽  
Combination Therapies ◽  
Second Line Chemotherapy ◽  
Line Chemotherapy

scholarly journals Effect of the Combination of Trabectedin and Pegylated Liposomal Doxorubicin in a BRCA2 Mutation Carrier with Recurrent Platinum-Sensitive Ovarian Cancer

2017 ◽  
Vol 10 (2) ◽  
pp. 433-437 ◽  
Author(s):  
María Jesús  Rubio Pérez
Keyword(s):  
Ovarian Cancer ◽  
Mutation Carrier ◽  
Liposomal Doxorubicin ◽  
Brca2 Mutation ◽  
Pegylated Liposomal Doxorubicin ◽  
Second Line ◽  
Brca2 Mutation Carrier ◽  
Second Line Chemotherapy ◽  
Platinum Sensitive ◽  
Line Chemotherapy

Introduction: The current standard of care for ovarian cancer is optimal cytoreduction with adjuvant chemotherapy based on a platinum/taxane combination. Although the response rate to this therapy is high, most patients ultimately relapse. Response to second-line therapy and prognosis are linked to the platinum-free interval (PFI); when both improve, the PFI increases. As a result, there is an increasing interest in the PFI extension strategies including platinum-free combinations. Case Presentation: A 50-year-old postmenopausal woman presented with ovarian serous carcinoma with peritoneal carcinomatosis. First-line neoadjuvant chemotherapy with carboplatin plus paclitaxel was initiated, followed by surgery and carboplatin plus paclitaxel chemotherapy. Eight months after the last cycle, CT revealed extensive supra- and infradiaphragmatic node involvement, and second-line chemotherapy was initiated with trabectedin and pegylated liposomal doxorubicin (PLD). Partial response was achieved and successfully maintained for 18 cycles. After the 18th cycle and a 25-month PFI, CT imaging evidenced disease progression. As the patient was a BRCA2 mutation carrier, third-line chemotherapy was initiated with carboplatin and gemcitabine every 3 weeks. After the third cycle, imaging confirmed complete response, which was maintained after the sixth and final cycle. Maintenance treatment with olaparib was initiated. At present – 6 months after the start of maintenance chemotherapy with olaparib – the patient is disease free. Conclusions: Second-line chemotherapy with a nonplatinum combination – trabectedin plus PLD – was effective in a BRCA2 mutation carrier with recurrent partially platinum-sensitive ovarian cancer.

CA-125 Values Predictive of Clinical Response during Second-Line Chemotherapy for Epithelial Ovarian Cancer

1989 ◽  
Vol 12 (2) ◽  
pp. 106-109 ◽  
Author(s):  
Laura W. Ng ◽  
Howard D. Homesley ◽  
Rolland J. Barrett ◽  
Charles E. Welander ◽  
L. Douglas Case
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Clinical Response ◽  
Ca 125 ◽  
Second Line ◽  
Second Line Chemotherapy ◽  
Line Chemotherapy

scholarly journals High-dose 5-fluorouracil and leucovorin as second-line chemotherapy in patients with platinum-resistant epithelial ovarian cancer

1995 ◽  
Vol 37 (1-2) ◽  
pp. 190-192 ◽  
Author(s):  
J. T. Kamphuis ◽  
M. C. Huider ◽  
G. J. Ras ◽  
C. A. H. Verhagen ◽  
I. Kateman ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
High Dose ◽  
Second Line ◽  
Second Line Chemotherapy ◽  
Platinum Resistant ◽  
Line Chemotherapy
Sign in / Sign up

Export Citation Format

Share Document